Lexaria Begins Investigational New Drug Enabling Program for DehydraTECH-CBD for Hypertension

Positive results using DehydraTECH-CBD support progressing to FDA IND application Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms today announced it is formally beginning the process towards an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”) with its DehydraTECH-processed cannabidiol (“DehydraTECH-CBD”) as a prospective registered pharmaceutical treatment for hypertension Lexaria has retained the services of an expert regulatory affairs and quality assurance consultancy group that will help prepare Lexaria for a pre-IND meeting with the FDA, as well as with designing the necessary non-clinical, clinical and related…

Lexaria Begins Investigational New Drug Enabling Program for DehydraTECH-CBD for Hypertension Topshelf News.

source https://topshelf.news/lexaria-begins-investigational-new-drug-enabling-program-for-dehydratech-cbd-for-hypertension/